Results 201 to 210 of about 511,618 (370)

The Crucial Findings Derived from the Special Issue "Inside Cancer Genomics: From Structure to Therapy". [PDF]

Cancers (Basel), 2023
Barresi V.
europepmc   +1 more source

bc10: A novel human bladder cancer‐associated protein with a conserved genomic structure downregulated in invasive cancer [PDF]

, 2002
Irina Gromova, Pavel Gromov, Julio E. Celis   +2 more
openalex   +1 more source

CRISPR targeting of FOXL2 c.402C>G mutation reduces malignant phenotype in granulosa tumor cells and identifies anti‐tumoral compounds

Molecular Oncology, Volume 19, Issue 4, Page 1092-1116, April 2025.
FOXL2 c.402C>G mutation drives granulosa cell tumors. Using CRISPR technology, we selectively corrected this mutation, reducing malignancy and increasing sensitivity to dasatinib and ketoconazole. Transcriptomic changes revealed potential therapeutic targets, demonstrating CRISPR's promise for treating this rare ovarian cancer.
Sandra Amarilla‐Quintana, Paloma Navarro, Iván Hernández, Alejandra Ramos, Ana Montero‐Calle, Pablo Cabezas‐Sainz, Maria J Barrero, Diego Megías, Borja Vilaplana‐Martí, Carolina Epifano, Déborah Gómez‐Dominguez, Sara Monzón, Isabel Cuesta, Laura Sánchez, Rodrigo Barderas, Jesús García‐Donas, Alberto Martín, Ignacio Pérez de Castro   +17 more
wiley   +1 more source

Screening of Germline BRCA1 and BRCA2 Variants in Nigerian Breast Cancer Patients

Technology in Cancer Research & Treatment
Background Breast cancer remains a leading cause of mortality among Nigerian women, with triple-negative breast cancer (TNBC) being particularly prevalent. Variations in BRCA1 and BRCA2 genes remain key risk factors for this disease.
Abimbola F. Onyia MSc, Paul Jibrin MBBS, Temitope Olatunji-Agunbiade MBBS, Ademola Oyekan MBBS, AbdulRazzaq Lawal MBBS, Adewumi Alabi MBBS, Anthonia C. Sowunmi MBBS, Eben A. Aje MBBS, Oluwabusayo B. Ogunniyi MBBS, Ebenezer S. Nkom MBBS, Opeyemi C. De Campos PhD, Oluwakemi A. Rotimi PhD, Jelili O. Oyelade PhD, Solomon O. Rotimi PhD   +13 more
doaj   +1 more source

Editorial: Prostate cancer genomics: Application at different stages of a patient's journey. [PDF]

Front Oncol, 2022
Poon DMC, Azad A, Castro E, Kanesvaran R, Sartor O.   +4 more
europepmc   +1 more source

Discovering Combinations of Genomic Aberrations Associated With Cancer [PDF]

, 2002
Michael A. Newton
openalex   +1 more source

Whole‐genome sequencing of cell‐free DNA reveals DNA of tumor origin in plasma from patients with colorectal adenomas

Molecular Oncology, Volume 19, Issue 4, Page 984-993, April 2025.
Tumor‐informed whole‐genome sequencing (MRD‐EDGESNV) was applied to detect circulating tumor DNA (ctDNA) in patients with colorectal adenomas. Using a 95% specificity threshold, established from stage III colorectal cancer patients, ctDNA was detected in 50% of symptomatic and 25% of asymptomatic adenoma cases with median tumor fractions of 5.9 × 10−5 ...
Amanda Frydendahl, Adam J. Widman, Nadia Øgaard, Anushri Arora, Daniel Halmos, Jesper Nors, Johanne Ahrenfeldt, Tenna V. Henriksen, Christina Demuth, Line Raaby, Mads H. Rasmussen, Christina Therkildsen, Dan A. Landau, Claus L. Andersen   +13 more
wiley   +1 more source

Imaging genomics of cancer: a bibliometric analysis and review

Cancer Imaging
Background Imaging genomics is a burgeoning field that seeks to connections between medical imaging and genomic features. It has been widely applied to explore heterogeneity and predict responsiveness and disease progression in cancer.
Xinyi Gou, Aobo Feng, Caizhen Feng, Jin Cheng, Nan Hong   +4 more
doaj   +1 more source

Multi-omics Pathways Workflow (MOPAW): An Automated Multi-omics Workflow on the Cancer Genomics Cloud. [PDF]

Cancer Inform, 2023
Nguyen T, Bian X, Roberson D, Khanna R, Chen Q, Yan C, Beck R, Worman Z, Meerzaman D.   +8 more
europepmc   +1 more source

Integration of single‐cell and bulk RNA‐sequencing data reveals the prognostic potential of epithelial gene markers for prostate cancer

Molecular Oncology, EarlyView.
Prostate cancer is a leading malignancy with significant clinical heterogeneity in men. An 11‐gene signature derived from dysregulated epithelial cell markers effectively predicted biochemical recurrence‐free survival in patients who underwent radical surgery or radiotherapy.
Zhuofan Mou, Lorna W. Harries
wiley   +1 more source